Related Experiment Video
Updated: May 8, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
Biosimilars: current scientific and regulatory considerations
Preeta Kaur Chugh, Vandana Roy1
1Department of Pharmacology, Vardhman Mahavir Medical College and Associated Safdarjung Hospital, House No. 73, G.F., Hemkunt Colony, Greater Kailash Part I, New Delhi 110048, India. docpreeta@yahoo.com.
Abstract:
The widespread use of biologics has paved way for newer options in therapeutics for once incurable illnesses. Their large and complex protein structure, post-translational modifications, elaborate manufacturing/production process and risk for immunogenicity adds to the uniqueness of a biologic product. Patent expiration of innovator biologics has led to the development of biosimilars; biologics similar /comparable to the reference product in terms of quality, safety and efficacy. We discuss the clinical safety and regulatory requirements for biosimilars in various countries across the world. Future holds promise for biosimilars to provide affordable, efficacious and safe treatment to a vast majority of patients with significant cost savings to the nation.
Related Concept Videos
Drug Products: Biologics, Biosimilars and Interchangeables
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Biopharmaceutical Factors Influencing Drug Product Design: Overview
Bioequivalence studies: Biowaivers
Bioequivalence: Overview
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...

